Revenue volatility remains a primary concern, highlighted by the 2026Q1 gross margin collapse to -2.5% following a period of 77.7% growth in 2025Q4.
| Sales/Revenue | 513.57M | 563.03M | 482.04M | 433.14M | 450.89M | 467.36M | 338.3M | 260.98M | 193.45M | 0 | 0 |
| Revenue Growth % | 11.95% | 16.8% | 11.29% | -3.94% | -3.52% | 38.15% | 29.63% | 34.91% | - | - | - |
| Cost of Goods Sold | 151.94M | 137.52M | 115.74M | 106.48M | 105.02M | 114.2M | 87.32M | 75.95M | 68.81M | 4.59M | 208.7K |
| COGS % of Revenue | - | 24.43% | 24.01% | 24.58% | 23.29% | 24.44% | 25.81% | 29.1% | 35.57% | - | - |
| Gross Profit | 361.62M | 425.51M | 366.3M | 326.66M | 345.87M | 353.16M | 250.98M | 185.03M | 124.64M | -4.59M | -208.7K |
| Gross Margin % | 70.41% | 75.57% | 75.99% | 75.42% | 76.71% | 75.56% | 74.19% | 70.9% | 64.43% | - | - |
| Gross Profit Growth % | - | 16.16% | 12.14% | -5.56% | -2.06% | 40.71% | 35.64% | 48.45% | 2814.41% | -2100.23% | - |
| Operating Expenses | 350.61M | 369.64M | 367.58M | 314.13M | 323.57M | 280.94M | 224.28M | 214.89M | 172.7M | 4.59M | 208.7K |
| OpEx % of Revenue | - | 65.65% | 76.26% | 72.52% | 71.76% | 60.11% | 66.3% | 82.34% | 89.28% | - | - |
| Selling, General & Admin | 318.91M | 326.24M | 294.51M | 269.75M | 283.81M | 250.2M | 204.19M | 200.09M | 161.96M | 4.59M | 208.7K |
| SG&A % of Revenue | - | 57.94% | 61.1% | 62.28% | 62.94% | 53.53% | 60.36% | 76.67% | 83.72% | - | - |
| Research & Development | 49.06M | 44.54M | 50.27M | 44.38M | 39.76M | 30.74M | 20.09M | 14.8M | 10.74M | 0 | 0 |
| R&D % of Revenue | - | 7.91% | 10.43% | 10.25% | 8.82% | 6.58% | 5.94% | 5.67% | 5.55% | - | - |
| Other Operating Expenses | -2.14M | -1.14M | 22.8M | 0 | 0 | 0 | 0 | 0 | 162K | 0 | 208.7K |
| Operating Income | 11.02M | 55.87M | -1.28M | 12.53M | 22.3M | 72.22M | 26.7M | -29.85M | -51.56M | -4.59M | 208.7K |
| Operating Margin % | 2.14% | 9.92% | -0.27% | 2.89% | 4.95% | 15.45% | 7.89% | -11.44% | -26.65% | - | - |
| Operating Income Growth % | - | 4454.56% | -110.24% | -43.84% | -69.12% | 170.48% | 189.44% | 42.09% | -1022.78% | -2300.23% | - |
| EBITDA | 44.04M | 82.81M | 15.74M | 35.97M | 40.34M | 88.89M | 34.88M | -20.03M | -44.58M | 1.04M | -208.7K |
| EBITDA Margin % | 8.58% | 14.71% | 3.27% | 8.31% | 8.95% | 19.02% | 10.31% | -7.67% | -23.04% | - | - |
| EBITDA Growth % | 2451.56% | 425.99% | -56.24% | -10.81% | -54.63% | 154.83% | 274.17% | 55.07% | -4402.21% | 596.49% | - |
| D&A (Non-Cash Add-back) | 33.02M | 26.94M | 17.03M | 23.45M | 18.03M | 16.68M | 8.18M | 9.83M | 6.98M | 5.63M | -417.4K |
| EBIT | 11.02M | 55.87M | -1.26M | 12.58M | 22.29M | 70.32M | 29.04M | -29.56M | -53.96M | -6.54M | -208.7K |
| Net Interest Income | 1.46M | 2.28M | -1.54M | -2.19M | -2.01M | -7.24M | -11.28M | -9M | -10.79M | -8.01M | -5.47M |
| Interest Income | 1.46M | 2.28M | 0 | 0 | 0 | 0 | 0 | 0 | 64K | 0 | 153K |
| Interest Expense | 0 | 0 | 1.54M | 2.19M | 2.01M | 7.24M | 11.28M | 9M | 10.85M | 8.01M | 5.63M |
| Other Income/Expense | -6.74M | -8.9M | -1.52M | -2.13M | -2.02M | -9.13M | -8.94M | -8.71M | -13.19M | 3.4M | 8.57M |
| Pretax Income | 4.28M | 46.97M | -2.81M | 10.39M | 20.28M | 63.09M | 17.76M | -38.56M | -64.75M | -2.09M | -208.7K |
| Pretax Margin % | 0.83% | 8.34% | -0.58% | 2.4% | 4.5% | 13.5% | 5.25% | -14.77% | -33.47% | - | - |
| Income Tax | 4.56M | 9.94M | -3.67M | 5.45M | 4.75M | -31.12M | 530K | 150K | 84K | -52.52K | -440.21K |
| Effective Tax Rate % | 106.64% | 21.16% | 130.67% | 52.42% | 23.42% | -49.32% | 2.98% | -0.39% | -0.13% | 2.51% | 210.93% |
| Net Income | -284K | 37.03M | 861K | 4.95M | 15.53M | 94.2M | 17.23M | -38.71M | -64.83M | -2.09M | -208.7K |
| Net Margin % | -0.06% | 6.58% | 0.18% | 1.14% | 3.44% | 20.16% | 5.09% | -14.83% | -33.51% | - | - |
| Net Income Growth % | 98.21% | 4201.05% | -82.59% | -68.16% | -83.51% | 446.61% | 144.52% | 40.29% | -2996.16% | -903.32% | - |
| Net Income (Continuing) | -284K | 37.03M | 861K | 4.95M | 15.53M | 94.2M | 17.23M | -38.71M | -64.83M | -2.09M | -208.7K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.09M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00 | 0.15 | -0.01 | 0.04 | 0.12 | 0.70 | 0.15 | -0.44 | -0.94 | -0.03 | -0.02 |
| EPS Growth % | 4.81% | 1600% | -126.81% | -68.92% | -82.86% | 366.67% | 134.09% | 53.19% | -2765.85% | -34.98% | - |
| EPS (Basic) | - | 0.16 | -0.01 | 0.04 | 0.12 | 0.73 | 0.16 | -0.44 | -0.94 | -0.03 | -0.02 |
| Diluted Shares Outstanding | 127.8M | 130.25M | 131.67M | 132.75M | 132.38M | 133.66M | 111.36M | 92.84M | 69.32M | 63.88M | 8.58M |
| Basic Shares Outstanding | 127.8M | 126.74M | 131.67M | 131.23M | 130.07M | 128.33M | 107.74M | 92.84M | 68.97M | 63.88M | 8.58M |
| Dividend Payout Ratio | - | - | 208.83% | - | - | - | - | - | - | - | - |
Reimbursement and regulatory volatility
As evidenced by the dramatic 57.1% revenue contraction reported in 2026Q1, Organogenesis faces significant top-line instability, contrasting sharply with the 77.7% growth observed in 2025Q4, which suggests that seasonal hospital budget cycles and reimbursement timing create extreme quarterly fluctuations that complicate long-term growth forecasting for investors.
The erratic revenue trajectory appears to be driven by the interplay between Medicare reimbursement timing and the company's reliance on specific product codes. Investors should monitor whether the recent contraction represents a structural shift in demand or merely a temporary misalignment of clinical adoption cycles.
According to the latest financial data, the company maintained gross margins near 75% for most of the observed period, though the 2026Q1 collapse to -2.5% highlights the extreme sensitivity of the cost structure to production volume and potential inventory obsolescence within the cold-chain distribution model.
While the company typically commands premium pricing for its bioengineered products, the recent margin collapse suggests that fixed manufacturing costs cannot be easily scaled down during periods of low demand. This indicates that the company's profitability is highly vulnerable to any disruption in the clinical application of its living cell therapies.
Based on reported income statements, SG&A expenses consistently hover between $65 million and $100 million per quarter, which indicates that the company has failed to achieve meaningful operating leverage as revenue growth has not consistently outpaced the high fixed costs of its direct sales force.
The persistent high level of SG&A relative to gross profit suggests that the company's high-touch, clinically-trained sales model is a significant drag on profitability. Unless the company can drive higher revenue per representative, operating margins will likely remain constrained by these structural overhead requirements.
As highlighted in recent regulatory filings, the company's heavy reliance on specific Medicare reimbursement codes creates a binary risk profile, where any adverse change in Local Coverage Determinations could render the current pricing model unsustainable and lead to further significant deterioration in net income margins.
Short-sellers would likely focus on the company's inability to maintain consistent profitability outside of peak seasonal quarters. The reliance on high-cost, specialized products in a tightening regulatory environment suggests that the current valuation may not fully account for the potential for permanent margin compression.
Quick answers to the most common questions about buying ORGO stock.
For fiscal year 2025, Organogenesis Holdings Inc. (ORGO) reported total revenue of $563.0M.
Organogenesis Holdings Inc. (ORGO) is profitable, generating $37.0M in net income for the fiscal year ending 2025 with a net profit margin of 6.6%.
Organogenesis Holdings Inc. (ORGO) reported an operating income of $55.9M, resulting in an operating profit margin of 9.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Organogenesis Holdings Inc. (ORGO) generated $425.5M in gross profit for the year, representing a gross profit margin of 75.6%. This demonstrates the company's core pricing power and production efficiency.